Berg

Berg joins Genomics England to sequence 100,000 genomes

Thursday, October 1, 2015

Berg, a Boston-based biopharmaceutical company, will join an industry collaboration with Genomics England. Formed by British Prime Minister David Cameron, Genomics England is partnering with health companies to accomplish its mission to sequence 100,000 human genomes and create a new genomic medicine service for the National Health Services (NHS) by 2017. The project focuses on patients with rare diseases and six common cancers.

[Read More]

Berg, the Parkinson’s Institute partner for clinical development

Friday, February 21, 2014

Berg and the Parkinson’s Institute and Clinical Center have announced the next phase in their ongoing partnership, focused on identifying potential biomarkers that may lead to breakthroughs in the research, diagnosis, and treatment of Parkinson’s disease. Using Berg’s Interrogative Biology platform to analyze multi-omic tissue samples (skin fibroblasts, blood, urine) supplied by the Parkinson’s Institute, this collaboration will identify the differences between healthy and diseased tissues in an effort to unravel the mysteries of Parkinson’s disease. Berg and the Parkinson’s Institute together are the first teams to approach biomarker discovery by looking at proteomics, metabolomics, and lipidomics, in addition to clinical data, simultaneously in human patients and controls from the same cohort.   

[Read More]

Berg, Icahn School of Medicine form R&D partnership

Monday, November 18, 2013

Berg, a biopharmaceutical company committed to a data-driven, biological research approach, and the Icahn School of Medicine at Mount Sinai have formed a five-year pharmaceutical and diagnostic R&D partnership to leverage the power of multi-omic biology and data analytics to obtain novel insights and potential therapeutics for cancer, central nervous system and endocrine disorders. Berg will leverage its Interrogative Biology platform in combination with Mount Sinai’s experience in big data, advanced analytics and biological network modeling.

[Read More]

Berg, Department of Defense partner for prostate cancer research

Friday, August 9, 2013

Berg, a biopharmaceutical company researching health solutions through a data-driven, biological research approach, has partnered with the U.S. Department of Defense (DoD) under a cooperative R&D agreement with the Uniformed Services University of the Health Sciences’ (USU) Center for Prostate Disease Research (CPDR) and The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) for prostate cancer research.

[Read More]